AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32990215 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 496
Study 32990215 — intervention group
Group type: COMPARATOR
Intervention: Active treatment and Placebo
Number of subjects: 496
Study 35334388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 70
Study 35334388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin administration
Number of subjects: 70
Study 35334388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 34959949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot-derived rhamnogalacturonan-I (cRG-I) at 0.3 g/day
Number of subjects: 177
Study 34959949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot-derived rhamnogalacturonan-I (cRG-I) at 1.5 g/day
Number of subjects: 177
Study 34959949 — intervention group
Group type: COMPARATOR
Intervention: Carrot-derived rhamnogalacturonan-I (cRG-I) at 0 g/day (control)
Number of subjects: 177
Study 36453726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone channeling augmentation
Number of subjects: 168
Study 36453726 — intervention group
Group type: COMPARATOR
Intervention: Standard repair
Number of subjects: 168
Study 33655813 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality gaming and physiotherapy
Number of subjects: 38
Study 33655813 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 38
Study 33642441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 223
Study 33642441 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 223
Study 34602065 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention for 10 weeks (0-10 weeks)
Number of subjects: 40
Study 34602065 — intervention group
Group type: COMPARATOR
Intervention: Usual care (delayed exercise) for 10 weeks (10-20 weeks)
Number of subjects: 40
Study 32889494 — intervention group
Group type: EXPERIMENTAL
Intervention: High closeness induction
Number of subjects: 69
Study 32889494 — intervention group
Group type: COMPARATOR
Intervention: Low closeness induction
Number of subjects: 69
Study 33067779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 6110
Study 33067779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6110
Study 33067779 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple statin treatment
Number of subjects: 6110
Study 33067779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lipophilic and hydrophilic statin
Number of subjects: 6110
Study 33067779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative defined daily dose (cDDD) > 430
Number of subjects: 6110
Study 33340779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D‐SWE examination with reliable measurements
Number of subjects: 788
Study 32127275 — intervention group
Group type: EXPERIMENTAL
Intervention: High heparin dose (600 IU/kg)
Number of subjects: 63
Study 32127275 — intervention group
Group type: COMPARATOR
Intervention: Low heparin dose (300 IU/kg)
Number of subjects: 63
Study 34003132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-generation synchronous telehealth program
Number of subjects: 391
Study 34003132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telehealth program)
Number of subjects: 391
Study 32683997 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM intervention
Number of subjects: 74
Study 36050617 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic paragastric autonomic neural blockade (PG-ANB)
Number of subjects: 145
Study 36050617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PG-ANB)
Number of subjects: 145
Study 34018181 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a quality improvement (QI) program including distance-learning strategies, involvement of a champion, regular submission of data on hospitalizations and root cause analyses of transfers, and training, feedback and support.
Number of subjects: 71
Study 34018181 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a quality improvement (QI) program
Number of subjects: 71
Study 34018181 — intervention group
Group type: COMPARATOR
Intervention: Low-performing NHs (control group)
Number of subjects: 71
Study 34511049 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lab4) plus 50 mg vitamin C
Number of subjects: 171
Study 34213106 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-tandem mass spectrometry (GC-MS/MS) method for cholesterol and tocopherols detection
Number of subjects: 20
Study 34213106 — intervention group
Group type: COMPARATOR
Intervention: National standard methods (GB 5009.82-2016, GB 5009.128-2016)
Number of subjects: 20
Study 34497506 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAR‐H1 lower‐limb exoskeletal robot
Number of subjects: 130
Study 34497506 — intervention group
Group type: COMPARATOR
Intervention: Routine training for walking (Control)
Number of subjects: 130
Study 33213530 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir plus standard treatment for COVID‐19 (loading dose of 3600mg on day 1, followed by 800mg 12 hours apart for 9 days)
Number of subjects: 302
Study 33213530 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COVID‐19 (at the discretion of the treating clinician)
Number of subjects: 302
Study 36180450 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Number of subjects: 144
Study 36180450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 144
Study 34151607 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient isolation treatment for COVID-19 patients
Number of subjects: 10
Study 34151607 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological experiences of COVID-19 patients
Number of subjects: 10
Study 36059240 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative narrative condition
Number of subjects: 1030
Study 36059240 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral narrative condition
Number of subjects: 1030
Study 36059240 — intervention group
Group type: COMPARATOR
Intervention: Positive narrative condition
Number of subjects: 1030
Study 36059240 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 1030
Study 34130022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose
Number of subjects: 120
Study 34130022 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC)
Number of subjects: 120
Study 34130022 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP)
Number of subjects: 120
Study 34130022 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF)
Number of subjects: 120
Study 36467732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women in third trimester (P3)
Number of subjects: 40
Study 36467732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women in second trimester (P2)
Number of subjects: 40
Study 36467732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women in second trimester (P2) and third trimester (P3)
Number of subjects: 40
Study 36467732 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women (N)
Number of subjects: 40
Study 36467732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women in first trimester (P1)
Number of subjects: 40
Study 36467732 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 35767081 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 0
Study 35767081 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32786068 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 95% VO2max
Number of subjects: 26
Study 32786068 — intervention group
Group type: COMPARATOR
Intervention: Cycling at 95% VO2max
Number of subjects: 26
Study 32786068 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 50% VO2max
Number of subjects: 26
Study 32786068 — intervention group
Group type: COMPARATOR
Intervention: Cycling at 65% VO2max
Number of subjects: 26
Study 34416183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) control
Number of subjects: 280
Study 34416183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) fluctuation
Number of subjects: 280
Study 34416183 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP fluctuation in primary angle closure glaucoma
Number of subjects: 280
Study 32900856 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-administered POCUS
Number of subjects: 204
Study 35906645 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care plus GAIN intervention (8-week interdisciplinary program)
Number of subjects: 180
Study 35906645 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care only
Number of subjects: 180
Study 35906645 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported outcomes
Number of subjects: 180
Study 35906645 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based outcomes
Number of subjects: 180
Study 32660658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA (60 mg/kg per d)
Number of subjects: 120
Study 32660658 — intervention group
Group type: COMPARATOR
Intervention: Soya oil (control)
Number of subjects: 120
Study 36084065 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVES
Number of subjects: 76
Study 36084065 — intervention group
Group type: EXPERIMENTAL
Intervention: IVES with an open circuit
Number of subjects: 76
Study 32505593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch non-ECG-triggered chest CT
Number of subjects: 1000
Study 34706340 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resisted sprint training (RST)
Number of subjects: 24
Study 34706340 — intervention group
Group type: COMPARATOR
Intervention: Unresisted sprint training (UST)
Number of subjects: 24
Study 34706340 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary soccer training and match play)
Number of subjects: 24
Study 34836084 — intervention group
Group type: EXPERIMENTAL
Intervention: SoMe social media literacy program
Number of subjects: 892
Study 34836084 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (lessons as usual)
Number of subjects: 892
Study 35038343 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face periodic occupational health screening
Number of subjects: 1077
Study 35038343 — intervention group
Group type: COMPARATOR
Intervention: Electronic screening with targeted follow-up
Number of subjects: 1077
Study 33287816 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) intravenously guttae for 7 days plus standard treatment: 1.5 mg/kg/day [day 1–3], 1 mg/kg/day [day 4–5], and 0.5 mg/kg/day [day 6–7]
Number of subjects: 171
Study 33287816 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 171
Study 33287816 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) treatment
Number of subjects: 171
Study 35466486 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 241
Study 34719279 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dressings
Number of subjects: 0
Study 34719279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Number of subjects: 0
Study 35795177 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 40
Study 35795177 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT)
Number of subjects: 40
Study 34480412 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity advice or exergame intervention
Number of subjects: 480
Study 34480412 — intervention group
Group type: COMPARATOR
Intervention: Not randomized to exergaming
Number of subjects: 480
Study 34480412 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 6MWT <300m
Number of subjects: 480
Study 34480412 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association class III/IV
Number of subjects: 480
Study 34480412 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of serum creatinine
Number of subjects: 480
Study 34480412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive function
Number of subjects: 480
Study 34480412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer anxiety symptoms
Number of subjects: 480
Study 32725411 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated drug-eluting stents (DES)
Number of subjects: 137
Study 32725411 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty with bail-out bare-metal stents (PTA ± BMS)
Number of subjects: 137
Study 35022480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic Contrast Enhanced Ultrasound (LCEUS) with Sonazoid injection
Number of subjects: 20
Study 33601934 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPSHOT intervention (32.5 contact hours)
Number of subjects: 132
Study 33601934 — intervention group
Group type: COMPARATOR
Intervention: Newsletter-only control group
Number of subjects: 132
Study 32267450 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of sugar-sweetened beverages
Number of subjects: 2172
Study 32267450 — intervention group
Group type: COMPARATOR
Intervention: Non-consumption of sugar-sweetened beverages
Number of subjects: 2172
Study 35585813 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 34
Study 35585813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 33407177 — intervention group
Group type: EXPERIMENTAL
Intervention: CnLN metastasis
Number of subjects: 1178
Study 33407177 — intervention group
Group type: EXPERIMENTAL
Intervention: pN2 patients with CnLN metastasis
Number of subjects: 1178
Study 33407177 — intervention group
Group type: EXPERIMENTAL
Intervention: pN3 patients with CnLN metastasis
Number of subjects: 1178
Study 36362489 — intervention group
Group type: EXPERIMENTAL
Intervention: Doll Therapy Intervention (DTI)
Number of subjects: 134
Study 36362489 — intervention group
Group type: COMPARATOR
Intervention: Sham Intervention (SI)
Number of subjects: 134
Study 33217829 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (MP)
Number of subjects: 226
Study 33217829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with midazolam (MS)
Number of subjects: 226
Study 33217829 — intervention group
Group type: COMPARATOR
Intervention: Propofol without midazolam (P)
Number of subjects: 226
Study 33217829 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane without midazolam (S)
Number of subjects: 226
Study 35389942 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation-REST
Number of subjects: 11
Study 35389942 — intervention group
Group type: COMPARATOR
Intervention: Passive sensory-stimulating control
Number of subjects: 11
Study 34301655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored educational intervention for general practitioners (GPs) including general training of PIMs and distribution of PIMs handbook
Number of subjects: 20
Study 34301655 — intervention group
Group type: COMPARATOR
Intervention: Routine practice by GPs in control arm
Number of subjects: 20
Study 35045835 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced autonomy
Number of subjects: 133
Study 35045835 — intervention group
Group type: COMPARATOR
Intervention: Routine autonomy
Number of subjects: 133
Study 35045835 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 133
Study 35045835 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention
Number of subjects: 133
Study 34639351 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Varnish (5% sodium fluoride with CPP‐ACP)
Number of subjects: 58
Study 34639351 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro White Varnish (5% sodium fluoride with fTCP)
Number of subjects: 58
Study 34639351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 58
Study 34543161 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg/day
Number of subjects: 127
Study 34543161 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 0.25 mg/kg/day
Number of subjects: 127
Study 34543161 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg/day (CKD subgroup)
Number of subjects: 127
Study 34543161 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 0.25 mg/kg/day (CKD subgroup)
Number of subjects: 127
Study 34543161 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg/day (non-CKD subgroup)
Number of subjects: 127
Study 34543161 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 0.25 mg/kg/day (non-CKD subgroup)
Number of subjects: 127
Study 33262414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 µg
Number of subjects: 158
Study 33262414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 33467972 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual reminiscence therapy (RT), 26 sessions, twice a week for 13 weeks
Number of subjects: 148
Study 33467972 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained treatment as usual
Number of subjects: 148
Study 34445009 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio Diet Score (PDS) assessed by food frequency questionnaire (FFQ)
Number of subjects: 652
Study 34445009 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio Diet Score (PDS) from FFQ
Number of subjects: 652
Study 34445009 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio Diet Score (PDS) from FFQ and 7DDR
Number of subjects: 652
Study 35248683 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practices plus Financial Incentives (BP + FI)
Number of subjects: 249
Study 35248683 — intervention group
Group type: COMPARATOR
Intervention: Best Practices (BP)
Number of subjects: 249
Study 35248683 — intervention group
Group type: COMPARATOR
Intervention: Never-Smokers (NS)
Number of subjects: 249
Study 36463502 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraining programme (knowledge and practical assessment and one-on-one retraining session)
Number of subjects: 130
Study 36463502 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 130
Study 33337947 — intervention group
Group type: EXPERIMENTAL
Intervention: α-hydroxyisocaproic acid
Number of subjects: 53
Study 33337947 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate free acid
Number of subjects: 53
Study 33337947 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium β-hydroxy-β-methylbutyrate
Number of subjects: 53
Study 33337947 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study 32087686 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral catheter analgesia
Number of subjects: 192
Study 32087686 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 192
Study 33742730 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dosages of hemofiltration for continuous RRT
Number of subjects: 211
Study 32788558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine
Number of subjects: 30
Study 32788558 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 30
Study 33306565 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine-tenofovir
Number of subjects: 224
Study 33306565 — intervention group
Group type: COMPARATOR
Intervention: lamivudine alone
Number of subjects: 224
Study 33273055 — intervention group
Group type: EXPERIMENTAL
Intervention: T21 policy implementation
Number of subjects: 0
Study 33657099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive dexamethasone
Number of subjects: 451
Study 32452181 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (Fengshi spine fixed-point rotation reduction plus routine dehydration and anti-inflammation)
Number of subjects: 59
Study 32452181 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 59
Study 32452181 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS score
Number of subjects: 59
Study 35015264 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 1 hour every 8 hours
Number of subjects: 50
Study 35015264 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (Control)
Number of subjects: 50
Study 33527419 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Movement Skill Competence (PMSC) and Stability (PMSC_Stability) pictorial scales
Number of subjects: 904
Study 33527419 — intervention group
Group type: COMPARATOR
Intervention: Körperkoordinations test für Kinder (KTK)
Number of subjects: 904
Study 32320088 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg)
Number of subjects: 797
Study 32320088 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (weight-based; 45 or 90 mg)
Number of subjects: 797
Study 35418312 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab plus chemotherapy
Number of subjects: 0
Study 35418312 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab plus chemotherapy in CD16A-158F allele carriers
Number of subjects: 0
Study 35418312 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0
Study 32870298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume group (6 mL/kg predicted body weight)
Number of subjects: 1236
Study 32870298 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume group (10 mL/kg predicted body weight)
Number of subjects: 1236
Study 34229578 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered care (PCC)
Number of subjects: 47
Study 34229578 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 47
Study 34380867 — intervention group
Group type: COMPARATOR
Intervention: Single-dose regimen of 4 L PEG (Nulytely) administered a day before the procedure
Number of subjects: 240
Study 34380867 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose regimen of 2 L PEG (Nulytely) given a day before and 2 L on the day of the procedure
Number of subjects: 240
Study 34380867 — intervention group
Group type: COMPARATOR
Intervention: Single-dose regimen of 4 L PEG (Nulytely)
Number of subjects: 240